Zorubicin  (Synonyms: Rubidazon; Rubidazone)

Zorubicin (Rubidazon) is a derivative of Daunorubicin (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas^{[1][2][3][4][5]}.

Zorubicin (0.1-1 μg/mL; 0-24 h) affects cell cycle^[2].
Zorubicin (0-128 nM/mL; 20 min) dose-dependently inhibits DNA polymerases α and β, and shows preferential inhibition of polymerase α^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Zorubicin (12-18 mg/kg; i.p. 48 h after tumour cells injection) affects leukaemic colony forming units^[1].
Zorubicin (0.75-6.0 mg/kg; i.v.) increases plasma histamine concentrations and produces immediate hypotension in anesthetized beagle dogs^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

645.66

C₃₄H₃₅N₃O₁₀

54083-22-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Alberts DS, Van Daalen Wetters T. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. Br J Cancer. 1976 Jul;34(1):64-8.  [Content Brief]

  [2]. Barlogie B, et al. Kinetic response to cultured human lymphoid cells to rubidazone. J Natl Cancer Inst. 1978 Feb;60(2):279-82.  [Content Brief]

  [3]. Herman EH, Young RS. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog. Cancer Treat Rep.  [Content Brief]

  [4]. Sartiano GP, et al. Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha. J Antibiot (Tokyo). 1979 Oct;32(10):1038-45.  [Content Brief]

  [5]. Akerman KJ, et al. Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I. J Am Chem Soc. 2014 Apr 16;136(15):5670-82.  [Content Brief]